Research programme: antisense CD40 inhibitors - Isis Pharmaceuticals/novosom AG

Drug Profile

Research programme: antisense CD40 inhibitors - Isis Pharmaceuticals/novosom AG

Latest Information Update: 23 Aug 2013

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer novosom AG
  • Class Antisense oligonucleotides
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Inflammation

Most Recent Events

  • 23 Aug 2013 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 23 Aug 2013 Discontinued - Preclinical for Inflammation in Germany (unspecified route)
  • 26 Aug 2008 novosom acquires licence to CD40-targeted antisense inhibitors from Isis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top